WithdrawnNot Applicable

Study of MSC-Exo on the Therapy for Intensively Ill Children

Stopped: Lacking of funding

China0Started 2022-09-01

Plain-language summary

At present, a number of projects related to MSCs have been approved for graft-versus-host disease, myocardial infarction, Crohn's disease and other diseases, indicating a strong therapeutic potential of MSCs. However, the efficacy of MSC-Exo for severely infected children is not fully evaluated. In our study, patients who met the inclusion criteria will be divided into trial group and control group. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. This study will evaluate the application and therapeutic effect of MSC-Exo in severely infected children, and determine the Optimal dosage and infusion.

Who can participate

Age range29 Days – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * children hospitalized in PICU of Children's Hospital of Fudan University Exclusion Criteria: * discharge within 48 hours * patients without informed consent * incomplete clinical and demographic data

What they're measuring

The death rate of children

Timeframe: within 28 days after they discharged from PICU

Marshall Multiple Organ Dysfunction Score

Timeframe: Within 3 to 15 days after the start of treatment

the APPS score

Timeframe: Within 3 to 15 days after the start of treatment

Trial details

NCT IDNCT04850469

SponsorChildren's Hospital of Fudan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-31

View on ClinicalTrials.gov More Sepsis trials